HC Wainwright Issues Positive Outlook for ITOS Earnings

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Investment analysts at HC Wainwright increased their Q1 2025 earnings estimates for iTeos Therapeutics in a report issued on Thursday, March 6th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($1.39) per share for the quarter, up from their prior estimate of ($1.44). HC Wainwright currently has a "Buy" rating and a $46.00 price target on the stock. The consensus estimate for iTeos Therapeutics' current full-year earnings is ($3.49) per share. HC Wainwright also issued estimates for iTeos Therapeutics' Q2 2025 earnings at ($1.44) EPS, Q3 2025 earnings at ($1.48) EPS, Q4 2025 earnings at ($1.53) EPS, FY2026 earnings at ($5.68) EPS, FY2027 earnings at ($3.46) EPS and FY2028 earnings at ($0.74) EPS.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($1.01) EPS for the quarter, beating analysts' consensus estimates of ($1.14) by $0.13.

Several other research analysts have also recently issued reports on the company. JPMorgan Chase & Co. lowered their price objective on iTeos Therapeutics from $22.00 to $15.00 and set an "overweight" rating for the company in a research report on Thursday, March 6th. Wells Fargo & Company lowered their price target on iTeos Therapeutics from $19.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, March 6th. Finally, Wedbush reissued an "outperform" rating and set a $25.00 price objective on shares of iTeos Therapeutics in a report on Wednesday, March 5th.

Remove Ads

iTeos Therapeutics Trading Up 6.5 %

NASDAQ:ITOS traded up $0.46 during trading hours on Monday, hitting $7.52. The company's stock had a trading volume of 671,594 shares, compared to its average volume of 453,291. iTeos Therapeutics has a 52-week low of $6.67 and a 52-week high of $18.75. The stock has a market capitalization of $287.22 million, a P/E ratio of -2.39 and a beta of 1.38. The stock has a fifty day moving average of $7.50 and a 200-day moving average of $9.20.

Institutional Trading of iTeos Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 DIFC Ltd acquired a new stake in shares of iTeos Therapeutics during the third quarter worth about $31,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in iTeos Therapeutics during the 4th quarter valued at approximately $42,000. Virtus ETF Advisers LLC lifted its position in iTeos Therapeutics by 58.2% during the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock worth $69,000 after acquiring an additional 3,293 shares during the period. Forefront Analytics LLC purchased a new position in shares of iTeos Therapeutics in the 4th quarter valued at approximately $85,000. Finally, Graham Capital Management L.P. acquired a new position in shares of iTeos Therapeutics in the fourth quarter valued at approximately $85,000. Institutional investors and hedge funds own 97.16% of the company's stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.